Can the Finnish Diabetes Risk Score (FINDRISC) be used to predict liver fibrosis risk instead of the fibrosis-4 index (FIB-4)?
Authors:
- 7 February 2026
- journal article
- research article
- Published by Oxford University Press (OUP) in Family Practice
- Vol. 43 (2)
Abstract
Background: FINDRISC is a non-invasive, easy-to-use, and free screening tool developed to estimate the 10-year risk of developing type 2 diabetes mellitus (T2DM). Objective: This study aimed to investigate whether FINDRISC can also predict liver fibrosis risk, as measured by the fibrosis-4 index (FIB-4) in individuals without a diagnosis of T2DM. Methods: This retrospective cross-sectional study included 1329 adults aged ≥18 years without prior T2DM, based on records from a Family Health Center in Turkey. The FINDRISC results used in T2DM screening were analyzed retrospectively from patient records. FINDRISC scores were calculated from questionnaire results, and FIB-4 was derived from laboratory data (age, alanine aminotransferase, aspartate aminotransferase, platelet count). Chi-square, correlation, and regression analyses were performed, adjusting for gender, smoking, alcohol use, physical activity, and marital status. Results: Mean FINDRISC scores and FIB-4 were 11.88 ± 6.22 and 1.01 ± 0.80, respectively. Higher FINDRISC categories were associated with older age, female sex, non-smoking, physical inactivity, and obesity. A moderate positive correlation was observed between FINDRISC and FIB-4 (rho = 0.427, P < 0.001). In multivariable regression, FINDRISC emerged as an independent predictor of FIB-4 (β = 0.250, P < 0.001), increasing model variance explained from 6.4% to 12.3%. Conclusion: FINDRISC, beyond its established role in T2DM risk stratification, may serve as a dual, non-invasive, and free screening tool to identify individuals at increased risk of liver fibrosis. Thanks to its simplicity and self-administered nature, individuals can easily complete the questionnaire at home, enabling early diagnosis of both T2DM and liver fibrosis risk.Keywords
This publication has 29 references indexed in Scilit:
- The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 DiabetesClinical Gastroenterology and Hepatology, 2024
- Liver fibrosis in pars cohort study: A large-scale study on the prevalence and correlated factorsArab Journal of Gastroenterology, 2023
- The prevalence of diabetes and associated risk factors among adult population in a Turkish population (Trabzon city)Primary Care Diabetes, 2022
- American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical SettingsEndocrine Practice, 2022
- Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver diseaseObesity, 2021
- Predicting type 2 diabetes mellitus among fishermen in Cape Coast: a comparison between the FINDRISC score and the metabolic syndromeJournal of Diabetes & Metabolic Disorders, 2020
- The effect of tobacco cessation on weight gain, obesity, and diabetes riskObesity, 2016
- Effects of exercise training on intrahepatic lipid content in humansDiabetologia, 2016
- Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysisJournal of Hepatology, 2012
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006